Academic Oncology Unit, Mount Vernon Cancer Centre, Northwood, Middlesex, UK.
J Magn Reson Imaging. 2012 Apr;35(4):745-63. doi: 10.1002/jmri.22838.
There is an increasing awareness that the evaluation of tumor response to oncologic treatments based solely on anatomic imaging assessments face many limitations, particularly in this era of novel biologic targeted therapies. Functional imaging techniques such as diffusion-weighted (DW) and dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) have the ability to depict important tumor biologic features and are able to predict therapy response based on assessments of cellularity and tumor vascularity, which often precede morphologic alterations. In this article we focus on DW-MRI and DCE-MRI as response parameters addressing the technologies involved, quantification methods, and validation for each technique and their current role in imaging response to conventional and novel therapies. We also discuss the challenges that lie ahead in the deployment of these imaging methods into the clinical environment.
人们越来越意识到，仅基于解剖成像评估来评价肿瘤对肿瘤治疗的反应存在许多局限性，特别是在新型生物靶向治疗时代。功能成像技术，如扩散加权（DW）和动态对比增强（DCE）磁共振成像（MRI），具有描绘重要肿瘤生物学特征的能力，并能够基于细胞密度和肿瘤血管生成的评估来预测治疗反应，而这些往往先于形态学改变。本文重点介绍 DW-MRI 和 DCE-MRI 作为反应参数，讨论涉及的技术、每种技术的量化方法和验证及其在常规和新型治疗反应成像中的当前作用。我们还讨论了将这些成像方法应用于临床环境所面临的挑战。
